All Chemistry World articles in Archive 2010-2015 – Page 31
-
News
Free trade could throttle generics from India
Upcoming trade agreements could stifle India's key role in supplying affordable Aids drugs to developing countries
-
News
One dimensional carbon chains get longer
Chemists have made the longest polyyne so far - linear chains of carbon atoms that resemble carbyne, an elusive form of one-dimensional carbon
-
News
Self-pumping membrane mimics cell machinery
Synthetic, self-pumping membranes could be use to generate energy in compartment-less fuel cells
-
PodcastTetrodotoxin
This week Simon Cotton investigates Tetrodoxotin (TTX), a poisonous chemical obtained from the fugu fish -
News
Warming worry shades ozone success
CFC replacements may have helped repair the hole in the ozone layer, but could contribute significantly to climate change
-
News
Salmonella's secret weapon
US researchers have explained the chemical trick behind Salmonella bacteria's ability to outgrow other microbes living in the gut
-
News
Catalyst improves prospects for fuel cells
Alkali ions on platinum make for a more viable water-gas shift reaction
-
News
UK faces scientific exodus
Heads of top universities warn that researchers will abandon the UK if cuts to science funding go ahead
-
News
Challenging aqua regia's throne
US researchers discover 'organic' aqua regia that can selectively dissolve noble metals in solution
-
News
End of the road for Avandia?
Risk of cardiac side effects finally causes GlaxoSmithKline's troubled diabetes drug to be pulled from European markets and severely restricted in the US
-
News
Structure dictates glycan story
Small structural differences in oligosaccharide clusters can lead to dramatic differences in the way they interact with the body
-
News
America's scientific lead remains on the brink
Despite investment, the outlook for US competitiveness has deteriorated over the last five years, says influential report
-
Business
Business roundup: October 2010
Sanofi bid too low says Genzyme Source: © SANOFI AVENTIS Christopher Viehbacher: ’offer provides immediate and certain value Sanofi-Aventis is not being bashful about its designs on Genzyme any longer. The French pharma giant has offered $69 (£45) per share in an all-cash bid that values the ...
-
Opinion
Editorial: Development goals
World leaders gathered in New York, US, at the end of September to attend a summit on the UN Millennium Development Goals
-
-
Feature
Artificial blood
Synthetic alternatives to donor blood have been stuck in development for decades. Nina Notman reports on recent promising progress
-
OpinionThe quiet comeback of 'combi-chem'
Derek Lowe investigates the comeback combinatorial chemistry has made in the field of drug discovery
-
Review
Priestley's good (and bad) companions
Joseph Priestley: friends and foes - remarkable lives in an age of revolution